Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy

• Published in: Breast (Edinburgh) Vol. 66; pp. 199 - 203
• Main Authors: Jeong, Jae Ho, Kim, Sung-Bae
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.12.2022; Elsevier
• Subjects: (s) from the Special Issue on: Antibody-drug Conjugates; Edited by Giuseppe Curigliano, Hope Rugo; Adjuvant; Antibody-drug conjugates; Antineoplastic Agents - therapeutic use; Breast Neoplasms - drug therapy; Early breast cancer; Female; Humans; Immunoconjugates - therapeutic use; Medical Oncology; Neoadjuvant; Sacituzumab govitecan; Triple Negative Breast Neoplasms - drug therapy; Trop-2; ADC; NACT; OS; TPC; Neoadjuvant; HR; Dato-DXd; Antibody-drug conjugates; DFS; Sacituzumab govitecan; SG; Trop-2; iDFS; Adjuvant; T-DM1; Early breast cancer; HER2; PFS; TNBC; pCR
• ISSN: 0960-9776; 1532-3080; 1532-3080
• DOI: 10.1016/j.breast.2022.10.015

Although breast cancer has a good prognosis compared with various cancers, metastatic breast cancer has an aggressive disease course and remains incurable. Therefore, treatment of early breast cancer to prevent recurrence and metastasis is crucial. Recently, the development of anti-cancer drugs, such as targeted agents and immuno-oncology, has been accelerating. Antibody-drug conjugates (ADCs) are also building a new paradigm. Particularly, ADCs targeting Trop-2 were approved for their efficacy in metastatic triple-negative breast cancer patients who received ≥2 prior systemic therapies and showed significant results in heavily pretreated hormone receptor-positive/HER2-negative breast cancer. In this brief review, we provide an overview of ongoing clinical trials of ADCs targeting Trop-2 in early breast cancer, specifically sacituzumab govitecan. •Antibody-drug conjugates (ADCs) are building a new paradigm in cancer treatment.•Sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) are ADCs targeting Trop-2.•SG and Dato-DXd showed improved efficacy in metastatic breast cancer treatment.•Several studies using SG are ongoing in the neoadjuvant/adjuvant setting for early breast cancer.